Analyst Reco. Tarsus Pharmaceuticals, Inc.

Equities

TARS

US87650L1035

Market Closed - Nasdaq Other stock markets 21:00:00 16/05/2024 BST			5-day change	1st Jan Change
38.58 ^USD	+0.21%		+3.29%	+90.52%

05-09	Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $61 From $59, Maintains Outperform Rating	MT
05-08	Transcript : Tarsus Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $61 From $59, Maintains Outperform Rating	05-09	MT
Goldman Sachs Adjusts Price Target on Tarsus Pharmaceuticals to $30 From $19, Maintains Neutral Rating	02-29	MT
Oppenheimer Raises Tarsus Pharmaceuticals Price Target to $59 From $55, Maintains Outperform Rating	02-28	MT
Goldman Sachs Starts Tarsus Pharmaceuticals With Neutral Rating, $19 Price Target	11-20	MT
HC Wainwright Adjusts Price Target on Tarsus Pharmaceuticals to $50 From $42, Keeps Buy Rating	11-10	MT
Guggenheim Raises Price Target on Tarsus Pharmaceuticals to $49 From $46, Maintains Buy Rating	11/09/23	MT
HC Wainwright Adjusts Tarsus Pharmaceuticals Price Target to $42 From $50, Maintains Buy Rating	11/08/23	MT
HC Wainwright Adjusts Price Target on Tarsus Pharmaceuticals to $50 From $44, Maintains Buy Rating	26/07/23	MT
William Blair Initiates Tarsus Pharmaceuticals at Outperform Rating	18/07/23	MT
HC Wainwright Adjusts Price Target on Tarsus Pharmaceuticals to $44 From $40, Keeps Buy Rating	26/06/23	MT
Guggenheim Raises Price Target on Tarsus Pharmaceuticals to $42 From $40, Maintains Buy Rating	16/06/23	MT
Guggenheim Initiates Coverage on Tarsus Pharmaceuticals With Buy Rating, $40 Price Target	18/05/23	MT
Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $43 From $66, Maintains Outperform Rating	10/11/22	MT
Barclays Starts Tarsus Pharmaceuticals at Overweight With $40 Price Target	01/08/22	MT
Oppenheimer Adjusts Price Target on Tarsus Pharmaceuticals to $66 From $55, Keeps Outperform Rating	03/05/22	MT
HC Wainwright Starts Tarsus Pharmaceuticals at Buy With $40 Price Target	21/12/21	MT
Oppenheimer Initiates Coverage on Tarsus Pharmaceuticals With Outperform Rating, $55 Price Target	23/11/21	MT
TARSUS PHARMACEUTICALS : Raymond James Adjusts Tarsus Pharmaceuticals' Price Target to $65 from $50, Keeps Strong Buy Rating	08/10/21	MT
TARSUS PHARMACEUTICALS : Raymond James Adjusts Tarsus Pharmaceuticals' Price Target to $50 From $39, Maintains Strong Buy Rating	29/06/21	MT
TARSUS PHARMACEUTICALS : Jefferies Adjusts Price Target on Tarsus Pharmaceuticals to $45 From $35, Reiterates Buy Rating	22/06/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Tarsus Pharmaceuticals, Inc.

Equities

TARS

US87650L1035

Analyst Reco.

Filters